POLR2I

Across TCGA pan-cancer cohorts, POLR2I mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of POLR2I’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where POLR2I mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types POLR2I is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

HNSC, PDAC, and LSCC are the cancer types where POLR2I tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in POLR2I mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.326	<.001	8	view →
PDAC	Female	II,III,IV	−0.362	<.001	6	view →
LSCC	Male	All	+0.121	<.001	5	view →
CCRCC	All	All	−0.109	.016	2	view →
LUAD	Male	III,IV	+0.162	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

POLR2I–HNSC

Open the HNSC breakdown →